Corrigendum to "Missed opportunities in HCV care: Trends in late diagnosis and treatment" [JHEP Reports 7 (2025) 101474] [0.03%]
关于“错过丙型肝炎治疗机会的遗漏：晚期诊断和治疗趋势”的勘误[JHEP报告7（2025）101474]
Shane Tillakeratne,Heather Valerio,Maryam Alavi et al.
Shane Tillakeratne et al.
[This corrects the article DOI: 10.1016/j.jhepr.2025.101474.]. © 2025 The Author(s).
Corrigendum to "Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFNα non-response" [J Hepatol (2025) 101382] [0.03%]
“慢性乙型肝炎病毒感染者常见的干扰素自身抗体与派格干扰素α应答无关”一文的勘误通知[J Hepatol (2025) 101382]
Douglas L Fink,David Etoori,Robert Hill et al.
Douglas L Fink et al.
[This corrects the article DOI: 10.1016/j.jhepr.2025.101382.]. © 2025 The Author(s).
Erratum to: "Liver resection and transplantation in the era of checkpoint inhibitors" JHEP Reports 2024 doi: 10.1016/j.jhepr.2024.101181 [0.03%]
关于“免疫检查点抑制剂时代下的肝切除和移植”的勘误：JHEP Reports 2024，doi: 10.1016/j.jhepr.2024.101181
Parissa Tabrizian,Rebecca Marino,Pierce K H Chow
Parissa Tabrizian
[This corrects the article DOI: 10.1016/j.jhepr.2024.101181.]. © 2025 The Author(s).
ESMO-MCBS v2.0: Advances, challenges, and perspectives in the assessment of clinical benefit in oncology [0.03%]
ESMO-MCBS V2.0：肿瘤学临床获益评估的进展、挑战和前景
Ezequiel Mauro,Miquel Serra-Burriel
Ezequiel Mauro
What we missed then, AI sees now: Revisiting legacy large extracellular vesicle data to reveal synergistic biomarkers for liver cancer screening [0.03%]
重新分析遗留的大型细胞外囊泡数据，AI发现肝癌筛查新的生物标志物组合
Arnulf G Willms,Marcin Krawczyk,Henrike Julich-Haertel et al.
Arnulf G Willms et al.
Background & aims: In our 2017 publication, we introduced a novel concept for liver cancer detection using large extracellular vesicles (EVs), specifically AnnV+EpCAM+ASGPR1+ tumor-associated microparticles. Despite promi...
Monique D Appelman,Thuc-Anh Nguyen,Andreas Oswald et al.
Monique D Appelman et al.
Background & aims: The sodium taurocholate cotransporting polypeptide (NTCP), the main hepatic uptake transporter of bile salts, is the docking receptor required for the HBV/HDV entry. However, the mechanism of NTCP-depen...
A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinoma [0.03%]
一种基于病理组学的多模态模型用于评估不可切除的肝内胆管癌化疗免疫疗效
Qi-Hang Cao,Han Li,Peng-Fei Sun et al.
Qi-Hang Cao et al.
Background & aims: Chemoimmunotherapy has emerged as the first-line therapy for unresectable intrahepatic cholangiocarcinoma (ICC). However, durable clinical responses are observed in less than 30% of patients, necessitat...
Point-of-care ultrasound of the inferior vena cava for intravascular volume assessment during intravenous albumin infusion in patients with cirrhosis [0.03%]
腔静脉超声在肝硬化患者人血白蛋白治疗过程中评估容量状态中的作用
Daniel Segna,Fabio Brazerol,Pompilia Radu et al.
Daniel Segna et al.
Background & aims: Current guidelines recommend intravenous (i.v.) albumin for different indications in decompensated cirrhosis, but iatrogenic hypervolemia following i.v. albumin is increasingly reported. We aimed to cha...
Mildly elevated liver lipid content is characterised by reduced insulin sensitivity [0.03%]
轻度肝脂升高表现为胰岛素抵抗降低
Nelli Tuomola,Eleni Rebelos,Aino Latva-Rasku et al.
Nelli Tuomola et al.
Background & aims: Recently, a new cut-off of ≤1.85% was proposed for normal liver lipid content based on a large population trial. In that study, people having liver lipid between 1.86% and the currently used magnetic r...
PSMA immunohistochemistry as a diagnostic biomarker of hepatocellular carcinoma [0.03%]
PSMA免疫组化作为诊断肝细胞癌的生物标志物
Killian Véron,Etienne Becht,Astrid Laurent-Bellue et al.
Killian Véron et al.
Background & aims: A combination of three immunohistological markers (Glypican 3, heat shock protein 70 [HSP70], and glutamine synthetase [GS]) is routinely used to differentiate hepatocellular carcinoma (HCC), but this p...